Are the current safety measures for the treatment of depression with esketamine sufficient?
Kyle Valentino, Kayla M Teopiz, Christine E Dri, Jennifer Swainson, Yang Jing Zheng, Roger S McIntyre
Expert Opinion on Drug Safety February 19, 2026 DOI: 10.1080/14740338.2026.2627184 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Keywords | Rems |
Abstract
1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...